Companies trading under general ticker variations resembling VG or specialized biotechnology entities like Voyager Therapeutics do not distribute cash dividends to their equity shareholders. As clinical-stage research and development enterprises focused on advancing genetic and neuropharmaceutical pipelines, these organizations consistently reinvest all available financial capital into ongoing laboratory research, preclinical testing, clinical trials, and corporate operational overhead rather than issuing regular dividend yields.